A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
Daiichi Sankyo
540 participants
May 21, 2024
INTERVENTIONAL
Conditions
Summary
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
12 mg/kg intravenous dose on Day 1 of each 21-day cycle
Topotecan will be administered per local SoC.
Amrubicin will be administered per local SoC.
Lurbinectedin will be administered per local SoC
Locations(230)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06203210